News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
846,735 Results
Type
Article (77883)
Company Profile (726)
Press Release (768107)
Multimedia
Podcasts (192)
Webinars (29)
Section
Business (229172)
Career Advice (3804)
Deals (39416)
Drug Delivery (151)
Drug Development (89841)
Employer Resources (205)
FDA (18178)
Job Trends (17238)
News (390473)
Policy (39068)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (3015)
Academic (2)
Accelerated approval (35)
Adcomms (36)
Allergies (154)
Alliances (56484)
ALS (183)
Alzheimer's disease (1809)
Antibody-drug conjugate (ADC) (357)
Approvals (18366)
Artificial intelligence (610)
Autoimmune disease (176)
Automation (40)
Bankruptcy (404)
Best Places to Work (12633)
BIOSECURE Act (23)
Biosimilars (206)
Biotechnology (450)
Bladder cancer (164)
Brain cancer (66)
Breast cancer (677)
Cancer (5129)
Cardiovascular disease (453)
Career advice (3262)
Career pathing (42)
CAR-T (314)
CDC (59)
Celiac Disease (2)
Cell therapy (843)
Cervical cancer (38)
Clinical research (75931)
Collaboration (1879)
Company closure (5)
Compensation (1195)
Complete response letters (75)
COVID-19 (2995)
CRISPR (101)
C-suite (914)
Cystic fibrosis (155)
Data (6407)
Decentralized trials (2)
Denatured (71)
Depression (152)
Diabetes (540)
Diagnostics (7255)
Digital health (52)
Diversity (13)
Diversity, equity & inclusion (49)
Drug discovery (296)
Drug pricing (226)
Drug shortages (36)
Duchenne muscular dystrophy (247)
Earnings (98061)
Editorial (67)
Employer branding (25)
Employer resources (174)
Events (134469)
Executive appointments (1048)
FDA (21431)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1582)
Gene editing (221)
Generative AI (61)
Gene therapy (687)
GLP-1 (1144)
Government (5429)
Grass and pollen (8)
Guidances (387)
Healthcare (20945)
HIV (66)
Huntington's disease (50)
IgA nephropathy (88)
Immunology and inflammation (301)
Immuno-oncology (66)
Indications (111)
Infectious disease (3295)
Inflammatory bowel disease (208)
Inflation Reduction Act (17)
Influenza (126)
Intellectual property (257)
Interviews (746)
IPO (17867)
IRA (61)
Job creations (5006)
Job search strategy (2639)
JPM (71)
Kidney cancer (17)
Labor market (96)
Layoffs (656)
Leadership (41)
Legal (9977)
Liver cancer (99)
Longevity (15)
Lung cancer (691)
Lymphoma (387)
Machine learning (44)
Management (66)
Manufacturing (872)
MASH (178)
Medical device (15039)
Medtech (15096)
Mergers & acquisitions (22636)
Metabolic disorders (1432)
Multiple sclerosis (170)
NASH (23)
Neurodegenerative disease (365)
Neuropsychiatric disorders (105)
Neuroscience (3162)
Neurotech (1)
NextGen: Class of 2026 (7664)
Non-profit (5118)
Now hiring (68)
Obesity (699)
Opinion (337)
Ovarian cancer (171)
Pain (219)
Pancreatic cancer (239)
Parkinson's disease (301)
Partnered (37)
Patents (522)
Patient recruitment (514)
Peanut (61)
People (65979)
Pharmaceutical (134)
Pharmacy benefit managers (33)
Phase 1 (23495)
Phase 2 (33078)
Phase 3 (24937)
Pipeline (5446)
Policy (342)
Postmarket research (3283)
Preclinical (10384)
Press Release (72)
Prostate cancer (253)
Psychedelics (58)
Radiopharmaceuticals (304)
Rare diseases (947)
Real estate (7244)
Recruiting (81)
Regulatory (28464)
Reports (68)
Research institute (2729)
Resumes & cover letters (593)
Rett syndrome (28)
RNA editing (21)
RSV (86)
Schizophrenia (162)
Series A (263)
Series B (204)
Service/supplier (27)
Sickle cell disease (105)
Special edition (27)
Spinal muscular atrophy (177)
Sponsored (48)
Startups (4251)
State (2)
Stomach cancer (20)
Supply chain (114)
Tariffs (101)
The Weekly (119)
Vaccines (1169)
Venture capital (100)
Weight loss (481)
Women's health (94)
Worklife (22)
Date
Last 7 days (660)
Last 30 days (2185)
Last 365 days (32231)
2026 (3731)
2025 (32678)
2024 (37924)
2023 (42566)
2022 (53928)
2021 (58722)
2020 (57665)
2019 (51315)
2018 (39097)
2017 (36881)
2016 (37855)
2015 (43894)
2014 (38687)
2013 (34844)
2012 (36758)
2011 (36798)
2010 (36403)
Location
Africa (1221)
Alabama (92)
Alaska (7)
Arizona (332)
Arkansas (14)
Asia (50180)
Australia (8627)
California (11777)
Canada (3373)
China (1201)
Colorado (501)
Connecticut (509)
Delaware (352)
Europe (114378)
Florida (1740)
Georgia (378)
Hawaii (4)
Idaho (67)
Illinois (965)
India (72)
Indiana (553)
Iowa (24)
Japan (448)
Kansas (133)
Kentucky (43)
Louisiana (30)
Maine (83)
Maryland (1473)
Massachusetts (8655)
Michigan (362)
Minnesota (673)
Mississippi (6)
Missouri (143)
Montana (36)
Nebraska (29)
Nevada (128)
New Hampshire (86)
New Jersey (3165)
New Mexico (33)
New York (3106)
North Carolina (1629)
North Dakota (10)
Northern California (5668)
Ohio (360)
Oklahoma (23)
Oregon (53)
Pennsylvania (2346)
Puerto Rico (25)
Rhode Island (51)
South America (1590)
South Carolina (68)
South Dakota (1)
Southern California (4552)
Tennessee (179)
Texas (1844)
United States (42364)
Utah (352)
Vermont (1)
Virginia (294)
Washington D.C. (88)
Washington State (984)
West Virginia (4)
Wisconsin (131)
Wyoming (2)
846,735 Results for "lvl technologies gmbh and co kg".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
February 2, 2026
·
9 min read
Press Releases
Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies
December 29, 2025
·
4 min read
Press Releases
BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations
August 15, 2024
·
3 min read
Deals
Luciole Medical AG Announces the Acquisition of Spiegelberg GmbH & Co. KG to Create a Leading Global Brain Monitoring Developer and Provider
Luciole Medical AG, a Swiss medical technology company specialized in brain monitoring, announced the acquisition of Spiegelberg GmbH & Co. KG, an established medical device company and provider of highly specialized devices and consumables for neurosurgery, from SHS Capital.
June 27, 2023
·
4 min read
Business
Rhinostics and LVL technologies Partner to Provide Decapping Solutions for Automated Collection Device Workflows
Rhinostics Inc. is excited to announce an expanded partnership with LVL technologies GmbH, which includes Rhinostics’ reselling of LVL’s decapper instrument and LVL’s distribution of Rhinostics’ automated collection devices in Germany and Austria.
November 14, 2022
·
5 min read
Press Releases
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU
February 1, 2026
·
9 min read
Press Releases
STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs
February 2, 2026
·
3 min read
Press Releases
Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
November 5, 2025
·
3 min read
Press Releases
Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform
November 3, 2025
·
4 min read
Press Releases
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound
January 12, 2026
·
5 min read
1 of 84,674
Next
